Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Medtronic

Last Updated: May 24, 2022

LUMASON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Lumason patents expire, and when can generic versions of Lumason launch?

Lumason is a drug marketed by Bracco and is included in one NDA. There are two patents protecting this drug.

This drug has nine patent family members in nine countries.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

DrugPatentWatch® Generic Entry Outlook for Lumason

Lumason was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2022. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for LUMASON
Drug patent expirations by year for LUMASON
Drug Prices for LUMASON

See drug prices for LUMASON

DrugPatentWatch® Estimated Generic Entry Opportunity Date for LUMASON
Generic Entry Date for LUMASON*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
NDA:
Dosage:
FOR SUSPENSION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUMASON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
United States Department of DefensePhase 4
Emory UniversityPhase 4
University of California, San FranciscoPhase 2

See all LUMASON clinical trials

US Patents and Regulatory Information for LUMASON

LUMASON is protected by two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LUMASON is See Plans and Pricing.

This potential generic entry date is based on NEW PATIENT POPULATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting LUMASON

Freeze-dried formulation for gas-filled microvesicles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Freeze-dried formulation for gas-filled microvesicles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting LUMASON

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LUMASON

See the table below for patents covering LUMASON around the world.

Country Patent Number Title Estimated Expiration
New Zealand 237637 INJECTABLE COMPOSITIONS OF GAS MICROBUBBLES AND A FILM-FORMING SURFACTANT See Plans and Pricing
South Africa 9308117 See Plans and Pricing
Spain 2192572 See Plans and Pricing
World Intellectual Property Organization (WIPO) 9409829 See Plans and Pricing
Russian Federation 2110991 MICRON AND SUBMICRON-SIZE MICROBEADS WITH POLYMER WRAP AND METHOD OF MANUFACTURING THEREOF See Plans and Pricing
Canada 2154867 MELANGES GAZEUX UTILES COMME AGENTS DE CONTRASTE ULTRASONORES (GAS MIXTURES USEFUL AS ULTRASOUND CONTRAST MEDIA) See Plans and Pricing
Austria 112173 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LUMASON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1556389 2015/074 Ireland See Plans and Pricing PRODUCT NAME: CEFTOLOZANE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR A SULFURIC ACID SALT; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
0619743 300061 Netherlands See Plans and Pricing PRODUCT NAME: ZWAVELHEXAFLUORIDE; REGISTRATION NO/DATE: EU/1/01/177/001 20010326
1556389 16C0004 France See Plans and Pricing PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
1556389 SPC/GB16/002 United Kingdom See Plans and Pricing PRODUCT NAME: CEFTOLOZANE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR A SULFURIC ACID SALT.; REGISTERED: UK EU/1/15/1032 20150922
0619743 C300061 Netherlands See Plans and Pricing PRODUCT NAME: ZWAVELHEXAFLUORIDE; REGISTRATION NO/DATE: EU/1/01/177/001-002 20010326
0619743 SPC/GB01/043 United Kingdom See Plans and Pricing PRODUCT NAME: SULPHUR HEXAFLUORIDE; REGISTERED: UK EU/1/01/177/001 20010326; UK EU/1/01/177/002 20010326
1345920 SPC/GB14/018 United Kingdom See Plans and Pricing PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
Medtronic
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.